Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized peginterferon alfa-2a plus ribavirin retreatment in HIV/HCV coinfected prior non-responders
2008-000859-10Phase 2Completed
- Sponsor
- ANRS
- Start
- Apr 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of peginterferon alfa-2a and ribavirin in hepatitis C virus infection, sponsored by ANRS. Primary endpoints: Rapid virologic response and Early virologic response. Started Apr 2008; status: completed.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2008-000859-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000859-10.